Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Accured Expenses (2016 - 2025)

Cytosorbents' Change in Accured Expenses history spans 15 years, with the latest figure at -$539000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$539000.0 for Q4 2025, down 139.69% from a year ago — trailing twelve months through Dec 2025 was -$706000.0 (up 60.95% YoY), and the annual figure for FY2025 was -$706000.0, up 60.95%.
  • Change in Accured Expenses for Q4 2025 was -$539000.0 at Cytosorbents, down from $193000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.1 million in Q4 2021 to a low of -$1.3 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is -$272603.0 (2022), against an average of -$86440.1.
  • The sharpest move saw Change in Accured Expenses crashed 490.9% in 2022, then soared 371.1% in 2023.
  • Year by year, Change in Accured Expenses stood at $2.1 million in 2021, then tumbled by 109.71% to -$206441.0 in 2022, then surged by 371.1% to $559666.0 in 2023, then soared by 142.64% to $1.4 million in 2024, then plummeted by 139.69% to -$539000.0 in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at -$539000.0, $193000.0, and $7282.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.